Researchers at Washington University School of Medicine have developed blood test "clocks" that can estimate when a person will start showing Alzheimer's symptoms, using a single protein marker called p-tau217. The study, published in Nature Medicine, analyzed 603 older adults and achieved predictions within a 3-4 year margin of error.
The timing depends heavily on age: individuals with elevated p-tau217 levels around age 60 typically don't develop symptoms for about 20 years, while those flagged around age 80 show symptoms within roughly 11 years. Over 7 million Americans currently live with Alzheimer's, costing nearly $400 billion annually.
Lead author Dr. Kellen Petersen and senior author Dr. Suzanne Schindler noted that blood tests are substantially cheaper and more accessible than brain imaging, potentially accelerating clinical trials for preventive treatments. The model is not yet accurate enough for individual clinical use but represents a major step toward affordable early detection.
